atai Life Sciences is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of mental health disorders. Founded in 2018, atai focuses on acquiring, incubating, and efficiently developing innovative therapeutics for conditions such as depression, anxiety, and addiction. Their diverse pipeline includes programs like RL-007 for cognitive impairment associated with schizophrenia and GRX-917 for anxiety disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines, striving to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.